Orlistat (Xenical and Alli): Increased Risk of Renal Failure

Orlistat, a drug marketed under the names of Alli and Xenical, is associated with an increased risk of developing renal failure … the final blow to anti-obesity drug …

Orlistat is the latest “anti-obesity pill ‘on the market, the others having been banned as too dangerous. This molecule has the effect of limiting the intestinal absorption of dietary fat, reducing calorie intake. Orlistat is available in two forms: Xenical ® Roche laboratories, only on medical prescription, and Alli ® (GlaxoSmithKline), less determined, but the counter in pharmacies. The latter is marketed in France since December 2009 and is a great success with more than 543,000 boxes sold.

Suspected to cause more severe side effects than benefits real Alli ® figure on the famous list of the French Agency for Safety of Health Products (AFSSAPS), drugs under surveillance.

A new study now confirms these suspicions. Canadian researchers show indeed, from a population of 1,000 patients taking Orlistat between 2002 and 2008, that the drug multiplies by 4 the risk of developing kidney failure.

In all cases, this information should be considered to properly evaluate the benefit / risk balance of these drugs against overweight …

Liked it
RSSPost a Comment
comments powered by Disqus